BEAM
Price
$26.74
Change
+$3.37 (+14.42%)
Updated
Dec 3 closing price
Capitalization
2.71B
89 days until earnings call
Intraday BUY SELL Signals
SABS
Price
$3.71
Change
+$0.07 (+1.92%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
180.91M
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs SABS

Header iconBEAM vs SABS Comparison
Open Charts BEAM vs SABSBanner chart's image
Beam Therapeutics
Price$26.74
Change+$3.37 (+14.42%)
Volume$2.66M
Capitalization2.71B
SAB Biotherapeutics
Price$3.71
Change+$0.07 (+1.92%)
Volume$2.63K
Capitalization180.91M
BEAM vs SABS Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. SABS commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and SABS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (BEAM: $23.37 vs. SABS: $3.67)
Brand notoriety: BEAM and SABS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 31% vs. SABS: 27%
Market capitalization -- BEAM: $2.44B vs. SABS: $180.91M
BEAM [@Biotechnology] is valued at $2.44B. SABS’s [@Biotechnology] market capitalization is $180.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileSABS’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • SABS’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than SABS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while SABS’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 5 bearish.
  • SABS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SABS is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а -5.35% price change this week, while SABS (@Biotechnology) price change was -6.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.71B) has a higher market cap than SABS($181M). SABS YTD gains are higher at: -3.273 vs. BEAM (-5.766). SABS has higher annual earnings (EBITDA): -33.47M vs. BEAM (-414.33M). BEAM has more cash in the bank: 1.15B vs. SABS (5.71M). SABS has less debt than BEAM: SABS (6.42M) vs BEAM (155M). BEAM has higher revenues than SABS: BEAM (60.3M) vs SABS (0).
BEAMSABSBEAM / SABS
Capitalization2.71B181M1,499%
EBITDA-414.33M-33.47M1,238%
Gain YTD-5.766-3.273176%
P/E RatioN/AN/A-
Revenue60.3M0-
Total Cash1.15B5.71M20,126%
Total Debt155M6.42M2,415%
FUNDAMENTALS RATINGS
BEAM: Fundamental Ratings
BEAM
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BEAMSABS
RSI
ODDS (%)
N/A
Bearish Trend 6 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
74%
Momentum
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 6 days ago
64%
MACD
ODDS (%)
Bullish Trend 6 days ago
87%
Bullish Trend 6 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 6 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
83%
Bullish Trend 6 days ago
71%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 10 days ago
73%
Declines
ODDS (%)
Bearish Trend 14 days ago
84%
Bearish Trend 14 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
83%
Aroon
ODDS (%)
Bearish Trend 6 days ago
82%
Bullish Trend 6 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
SABS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRIRX80.11N/A
N/A
Nuveen Large Cap Gr Idx Retire
TINCX2.85N/A
N/A
Templeton Global Dynamic Income A1
UIAGX80.68N/A
N/A
Victory Aggressive Growth Institutional
UGEIX13.03N/A
N/A
Victory Global Equity Income
TOTFX11.70N/A
N/A
Transamerica Mid Cap Value Opps R4

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-2.83%
CRSP - BEAM
70%
Closely correlated
-1.13%
RXRX - BEAM
61%
Loosely correlated
-0.69%
NTLA - BEAM
61%
Loosely correlated
-3.74%
PRME - BEAM
60%
Loosely correlated
-5.71%
AXON - BEAM
57%
Loosely correlated
+0.91%
More

SABS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SABS has been loosely correlated with MGX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then MGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SABS
1D Price
Change %
SABS100%
-3.17%
MGX - SABS
38%
Loosely correlated
-3.13%
TECX - SABS
32%
Poorly correlated
-7.01%
BEAM - SABS
29%
Poorly correlated
-2.83%
INKT - SABS
28%
Poorly correlated
-2.07%
SLS - SABS
26%
Poorly correlated
-7.33%
More